EUVIMEDEUVIMED entdecken
Crossref

Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis

Parastoo Babakinejad, Rebecca Lapsley, Lara Forster, Stuart McPherson, Mark S Pearce, Nick J Reynolds, Emma Slack, Sophie C Weatherhead, Philip J Hampton

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Parastoo Babakinejad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Royal Victoria Infirmary, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Methotrexate, Psoriasis, Liver Cirrhosis, Elasticity Imaging Techniques. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Medical Research Council, Newcastle upon Tyne Hospitals NHS Foundation Trust, Psoriasis Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are established risk factors for liver fibrosis (LF), but data on the impact of methotrexate on LF in patients with psoriasis are lacking.

Objectives

This cross-sectional study aimed to determine the prevalence of LF in patients with psoriasis and to evaluate the relationship between LF, cumulative methotrexate dose and other LF risk factors.

Methods

Adults with a history of moderate-to-severe chronic plaque psoriasis were recruited between June 2020 and March 2021. Patients underwent transient elastography to evaluate LF. Three values for liver stiffness measurement (LSM) were assessed, indicating mild or worse LF (≥ 7 kPa), moderate or worse LF (≥ 7.9 kPa) and advanced LF (≥ 9.5kPa). Cumulative methotrexate dose and other potential risk factors for LF were assessed.

Results

Overall, 240 patients were recruited and 204 participants with valid LSM values were included in the analysis [median age 48 years [interquartile range (IQR) 37–57]; 51% female sex; 56% body mass index (BMI) ≥ 30 (kg m−2) and a median Alcohol Use Disorders Identification Test (AUDIT) score of 4 (IQR 1–7, 23% score ≥ 8)]. In total, 91% had received methotrexate [median duration 36 months (IQR 14–78)]. Prevalence of LF was 36%, 25% and 17% using LSM ≥ 7 kPa, ≥ 7.9 kPa and ≥ 9.5 kPa, respectively. There was no association between cumulative methotrexate dose [median 2.16 (IQR 0.93–5.2)] and continuous LSM values [unstandardized coefficient 0.16, 95% confidence interval (CI) −0.49 to 0.82, P = 0.626] or using the categorical LSM cutoff values: ≥ 7 kPa [unadjusted odds ratio 1.06 (95% CI 0.97–1.15), P = 0.192], ≥ 7.9 kPa [unadjusted odds ratio 1.03 (95% CI 0.94–1.12), P = 0.577] and ≥ 9.5 kPa (unadjusted odds ratio 1.01, 95% CI 0.91–1.12; P = 0.843). The following risk factors were associated with higher LSM values: BMI (P ≤ 0.001), waist circumference (P ≤ 0.001), metabolic syndrome (P ≤ 0.001), AUDIT score (P = 0.020) and FIB-4 score (P = 0.03). BMI ≥ 28, diabetes and metabolic syndrome were shown to be better predictors of LF compared with FIB-4 score.

Conclusions

This study confirms a high prevalence of significant LF in patients with psoriasis. Cumulative methotrexate dose was not associated with LF. Patients with BMI ≥ 28, metabolic syndrome and diabetes are at higher risk for LF. These risk factors may help to identify when a more detailed liver health assessment is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexatePsoriasisLiver CirrhosisElasticity Imaging TechniquesHumansFemaleMaleMiddle AgedCross-Sectional StudiesAdultRisk FactorsPrevalenceDermatologic AgentsSeverity of Illness IndexDose-Response Relationship, Drug

Substanzen

MethotrexateDermatologic Agents

Autor:innen und Institutionen

  • Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Liver unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Newcastle Biomedical Research Centre (BRC), Newcastle upon Tyne, UK.

Förderung

  • Medical Research Council
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Psoriasis Association
  • NIHR
  • NIHR Newcastle Patient Safety Research Collaborative
  • an NIHR predoctoral fellowship in epidemiology
  • NIHR Newcastle In Vitro Diagnostics Cooperative
  • AiM

Zitieren

APA

Babakinejad, P., Lapsley, R., Forster, L., McPherson, S., Pearce, M. S., Reynolds, N. J., Slack, E., Weatherhead, S. C., & Hampton, P. J. (2024). Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae069

Vancouver

Babakinejad P, Lapsley R, Forster L, McPherson S, Pearce MS, Reynolds NJ, et al. Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae069

BibTeX
@article{Babakinejad2024,
  author = {Babakinejad, Parastoo and Lapsley, Rebecca and Forster, Lara and McPherson, Stuart and Pearce, Mark S and Reynolds, Nick J and Slack, Emma and Weatherhead, Sophie C and Hampton, Philip J},
  title = {Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae069}
}
Kostenlos starten →